Introduction {#s1}
============

Recent reports estimate that 1 in 5 adults worldwide are affected by a mental health disorder, with anxiety and depression being the most common affecting more than 260 million people ([@bib20]). Most current pharmacotherapies to treat these disorders target serotonin receptors or serotonin clearance. The dorsal raphe nucleus is the largest serotonergic nucleus in the brain and the predominant source of central serotonin (5-HT). In vivo, tonic noradrenergic input to the dorsal raphe that activates Gα~q/11~ protein-coupled α1-adrenergic receptors (α1-A~R~s) is required for 5-HT neurons to fire action potentials ([@bib5]; [@bib4]) and release 5-HT ([@bib12]). In dorsal raphe brain slices, synaptic activation of α1-A~R~s produces a slow membrane depolarization lasting tens of seconds ([@bib66]). Despite having a crucial role in regulating 5-HT neuron excitability, the ion channels responsible for the depolarization remain unknown.

Throughout the central and peripheral nervous system, activation of Gα~q/11~ protein-coupled receptors (G~q~PCRs), namely metabotropic glutamate mGlu~R~s, muscarinic acetylcholine M1 (mACh~R~s), or α1-A~R~s produces slow, noisy inward currents. Multiple mechanisms have been reported to underlie the inward current including: inhibition of K^+^ current (including leak, Ca^2+^-activated, and Kv7/M-current) ([@bib8]; [@bib26]; [@bib47]; [@bib56]), modulation of TTX-sensitive persistent Na^+^ current ([@bib65]), and activation of transient potential receptor canonical (TRPC) ([@bib29]; [@bib37]), Na^+^-leak (NALCN) ([@bib44]), or delta glutamate receptor-channels ([@bib1]; [@bib7]).

The delta glutamate receptors, GluD1~R~ and GluD2~R~, are mysterious members of the ionotropic glutamate receptor family in that they are not gated by glutamate ([@bib2]; [@bib43]). One theory is that they are strictly scaffolding proteins or synaptic organizers, rather than ion conducting channels. But wild-type channels have been reported to conduct in response to activation of mGlu~R~s ([@bib1]; [@bib7]). GluD1~R~ (*Grid1*) mRNA is expressed widely throughout the brain, with notably high levels in the dorsal raphe ([@bib30]; [@bib41]). Here, we used a combination of in vitro patch-clamp electrophysiology and pharmacology with a CRISPR/Cas9 viral genetic strategy to determine that activation of α1-A~R~s in the dorsal raphe depolarizes neurons via GluD1~R~-channel conductance. We utilize the α1-A~R~-GluD1~R~-EPSC to explore conduction and biophysical properties of GluD1~R~-channels, to ultimately glean a greater understanding of GluD1~R~-channel gating. Lastly, we demonstrate that functional deletion of GluD1~R~-channels in the dorsal raphe produces an anxiogenic behavioral phenotype.

Results {#s2}
=======

Synaptic activation of α1-adrenergic receptors produces an EPSC {#s2-1}
---------------------------------------------------------------

Electrophysiological recordings were made from dorsal raphe neurons in acute brain slices from wild-type mice at 35° C in the presence of NMDA~R~, AMPA~R~, Kainate~R~, GABA-A~R~, and 5-HT1A~R~ antagonists. With cell-attached recordings, a train of 5 electrical stimuli (60 Hz), delivered to the brain slice via a monopolar stimulating electrode, produced firing in previously quiescent neurons, which was blocked by application of the α1-A~R~ antagonist, prazosin (100 nM, [Figure 1A](#fig1){ref-type="fig"}). The excitation produced 20±5 action potentials that lasted 9.0±3.0 s, with a latency of 650.6±0.1 ms from onset of stimulation to the first action potential ([Figure 1B-E](#fig1){ref-type="fig"}). In whole-cell recording using a potassium-based internal solution, the same train of electrical stimuli produced prolonged action potential firing ([Figure 1F](#fig1){ref-type="fig"}). In voltage-clamp mode (V~hold~ -65 mV), the same stimulation produced a slow and long-lasting (27.4±2.3 s, n=10) excitatory postsynaptic current (EPSC, [Figure 1F](#fig1){ref-type="fig"}) that was eliminated by the application of prazosin ([Figure 1G](#fig1){ref-type="fig"}). Prazosin had no effect on basal whole-cell current (-3.8±3.4 pA, p=0.232, n=10, data not shown) indicating a lack of persistent inward current due to noradrenaline tone. On average, the duration of the α1-A~R~-EPSC was orders of magnitude longer than fast AMPA~R~ channel-mediated EPSCs (\~10^3.5^×) and \~18× longer than 'slow' 5-HT1A receptor-G protein-coupled inwardly rectifying potassium channel (GIRK)-dependent IPSCs ([@bib17]; [Figure 1H](#fig1){ref-type="fig"}). To test whether α1-A~R~-EPSCs were dependent on G protein-signaling, recordings were made with an internal solution containing GDPβS-Li~3~ (1.8 mM) in place of GTP. Disruption of G protein signaling with intracellular dialysis of GDPβS-Li~3~ eliminated the α1-A~R~-EPSC within 5-20 mins post-break-in (p=0.004, n=9), whereas dialysis with LiCl alone had no effect on the amplitude of the α1-A~R~-EPSC (p=0.625, n=4, [Figure 1I](#fig1){ref-type="fig"}). These findings demonstrate a cell-autonomous requirement of G protein signaling in the generation of the α1-A~R~-EPSC. Application of tetrodotoxin (1 μM) reversibly abolished the α1-A~R~-EPSC, demonstrating a dependence on presynaptic action potentials ([Figure 1J](#fig1){ref-type="fig"}). Disruption of the vesicular monoamine transporter with reserpine (1 μM) or removal of external Ca^2+^ also eliminated the α1-A~R~-EPSC, indicating noradrenaline release is vesicular ([Figure 1K and L](#fig1){ref-type="fig"}).

![Electrical stimulation evokes long-lasting action potential firing produced by an α1-adrenergic receptor-dependent EPSC.\
(**A**) Representative traces of cell-attached recording where stimulation of the brain slice (5 stims at 60 Hz) produced action potential firing that was abolished by application of the α1-adrenergic receptor antagonist, prazosin (100 nM). (**B**) Plot of number of action potentials showing the stimulation-induced increase in frequency (p=0.004, n = 6). (**C**) Plot of duration of action potential firing. (**D**) Plot of mean instantaneous frequency of action potential firing over the first 10 s of firing. (**E**) Plot of the latency from stimulation onset to the first action potential. (**F**) Example whole-cell recordings in the same cell, where electrical stimulation of the slice produced prolonged action potential firing in current-clamp (upper trace) and a slow EPSC in voltage-clamp mode (lower trace). (**G**) Bath application of prazosin eliminated the slow EPSC shown in a representative trace (left, baseline adjusted) and in grouped data (right, p=0.002, n = 10). (**H**) Representative traces of a whole-cell recording when the brain slice was stimulated in the absence of antagonists showing the kinetics of the α1-A~R~-EPSC relative to the fast EPSC (peak has been truncated) and 5HT1A~R~-IPSC (left). Subsequent addition of AMPA~R~/Kainate~R~ and GABA-A~R~ and 5-HT1A~R~ antagonists revealed the remaining synaptic current produced by α1-A~R~ activation (right). Time of stimulations are marked by arrows. (**I**) With GDPβS-Li~3~-containing internal solution, the amplitude of the α1-A~R~-EPSC ran down within \~5--20 min of break-in to whole-cell mode; shown in a plot compared with control internal solution containing LiCl only (left) and in grouped data (right, p=0.004, n = 9, 1^st^: first EPSC; post: post-dialysis). (**J**) Bath application of tetrodotoxin (TTX, 1 μM) reversibly eliminated the α1-A~R~-EPSC shown in a representative trace (left, α1-A~R~-EPSC evoked every 90 s (arrows)) and in grouped data (right, p=0.009, n = 4). (**K**) Plot of the inhibition of α1-A~R~-EPSC amplitude by application of reserpine (res, 1 μM, p=0.016, n = 7). (**L**) Plot of the inhibition of α1-A~R~-EPSC amplitude by removal of external Ca^2+^ (0\[Ca^2+^\]~o~, p=0.0001, n = 14). Line and error bars represent mean ± SEM, \* denotes statistical significance.\
Figure 1---source data 1.Numerical data that were used to generate graphs in [Figure 1](#fig1){ref-type="fig"}.](elife-56054-fig1){#fig1}

Biophysical properties of the channel {#s2-2}
-------------------------------------

Under our recording conditions, resistance of the membrane (R~m~) significantly decreased during the α1-A~R~-EPSC, indicative of opening of ion channels ([Figure 2A](#fig2){ref-type="fig"}). Membrane noise variance (σ^2^) increased significantly during the EPSC compared to membrane noise under basal conditions ([Figure 2B and C](#fig2){ref-type="fig"}). The α1-A~R~-EPSC σ^2^ -- amplitude relationship was well fit by linear regression, suggestive of a consistent conductance state, yielding an estimate of a -1.16 pA unitary current ([Figure 2D](#fig2){ref-type="fig"}). Voltage ramps from -120 to -10 mV (1 mV/10 ms) before and during the α1-A~R~-EPSC ([Figure 2E](#fig2){ref-type="fig"}) showed that the current reversed polarity at -28.6±2.4 mV ([Figure 2E-G](#fig2){ref-type="fig"}). Exogenous application of noradrenaline (30 μM, in the presence of α2-A~R~ antagonist, idazoxan, 1 μM) produced an inward current (I~NA~) with a similar reversal potential (-25.1±2.9 mV, [Figure 2G](#fig2){ref-type="fig"}). Replacing extracellular Na^+^ (126 mM) with N-methyl D-glucamine (NMDG) completely abolished inward I~NA~, suggesting Na^+^ as the prominent charge carrier ([Figure 2H](#fig2){ref-type="fig"}). Increasing extracellular K^+^ from 2.5 to 6.5 or 10.5 mM, expected to shift E~k~ from -107 to -81 and -69 mV, respectively, had no effect on the amplitude of the α1-A~R~-EPSC at V~hold~ -65 mV ([Figure 2I](#fig2){ref-type="fig"}) nor -120 mV (p=0.692, n=11, data not shown), but produced a significant depolarizing shift in E~rev~ of the α1-A~R~-EPSC ([Figure 2J](#fig2){ref-type="fig"}), suggesting the channel is also permeable to K^+^, and may be 2-3× as permeable to K^+^ as Na^+^. Removal of external MgCl~2~ had no significant effect on E~rev~ (-28.5±5.7 mV), nor on the amplitude of I~NA~ ([Figure 2K and L](#fig2){ref-type="fig"}). Removal of external CaCl~2~ also had no effect on E~rev~ (-30.3±3.5 mV) but significantly augmented inward I~NA~, ([Figure 2K and L](#fig2){ref-type="fig"}). Taken together, the data suggest that α1-A~R~-dependent current, whether produced by vesicular release of noradrenaline or exogenous noradrenaline application is carried through a mixed cation channel, with inward current carried predominantly by Na^+^ entry. Here, measurements of E~rev~ assume voltage-independence of the channel and the signaling mechanism by which α1-A~R~ signal to the channel. To test for voltage-dependence, we employed a two-pulse voltage-step protocol. Current was measured at V~hold~ -120 mV following a conditioning pre-pulse (-120 to 30 mV, 150 ms) before and after application of noradrenaline ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). I~NA~ was isolated by subtracting the current under basal conditions from the current during noradrenaline. Conductance (G~NA~) was calculated, using an E~rev~ of -25.1 mV. Conditioning depolarizing pre-pulses incrementally reduced G~NA~ and the increase in membrane noise induced by noradrenaline measured at V~hold~ -120 mV ([Figure 2---figure supplement 1C and D](#fig2s1){ref-type="fig"}), demonstrating voltage-dependence of inward I~NA~, such that depolarization reduced conductance.

![α1-adrenergic receptor-dependent inward current is carried by sodium entry.\
(**A**) Membrane resistance (R~m~, ΔV −65 to −120 mV) decreased during the α1-A~R~-EPSC indicating an opening of ion channels, as shown in an example trace (left) and in grouped data (right, p\<0.0001, n = 31). (**B**) Representative trace of membrane noise during the α1-A~R~-EPSC, brackets denote segments shown below on an expanded scale. (**C**) Membrane noise (variance, σ^2^) increased during the α1-A~R~-EPSC (p\<0.0001, n = 22). (**D**) Plot of α1-A~R~-EPSC variance versus mean amplitude, linear fit represents mean unitary current (*i*, r^2^ = 0.713, p\<0.0001). (**E**) Slow voltage ramps (1 mV/10 ms, analyzed from −120 to −10 mV) were used to determine the current-voltage relationship of the α1-A~R~-EPSC (subtraction), determined by subtracting current at the peak of the α1-A~R~-EPSC (stim) from current measured in control conditions just prior to stimulation (basal). Current generated during ramps were truncated for clarity. (**F**) Current-voltage relationship of the α1-A~R~-EPSC from grouped data. Shaded area represents mean ± SEM. (**G**) Plot of reversal potentials (E~rev~) of the α1-A~R~-EPSC and I~NA~ (p\>0.999, n = 26 and 14). (**H**) Replacing 126 mM NaCl with NMDG eliminated inward I~NA~, shown in a time-course plot (V~hold~−65 mV, p\<0.0001, n = 14 and 13). (**I**) Plot of α1-A~R~-EPSC amplitudes measured at V~hold~−65 mV, in 2.5, 6.5, and 10.5 mM \[K^+^\]~o~ (p=0.162, n = 17). (**J**) Plot of α1-A~R~-EPSC reversal potential (E~rev~) with varying concentration of external K^+^ (\[K^+^\]~o~), demonstrating a depolarizing shift in E~rev~ as external K^+^ was increased (p=0.010, n = 26, 10, and 11). (**K**) Plot of reversal potentials (E~rev~) of I~NA~, demonstrating no significant difference between control conditions (ctrl), and after removal of external Ca^2+^ (0\[Ca^2+^\]~o~, p=0.49, n = 14 and 12) or Mg^2+^ (0\[Mg^2+^\]~o~, p=0.73, n = 14 and 11). (**L**) Plot of the amplitude of I~NA~ (V~hold~−65 mV) demonstrating an augmented I~NA~ amplitude in 0\[Ca^2+^\]~o~ (p=0.017, n = 14), but not in 0\[Mg^2+^\]~o~, (p\>0.9999, n = 11) as compared with control conditions (n = 14). Line and error bars represent mean ± SEM, \* denotes statistical significance, ns denotes not significant.\
Figure 2---source data 1.Numerical data that were used to generate graphs in [Figure 2](#fig2){ref-type="fig"}.](elife-56054-fig2){#fig2}

α1-adrenergic receptors modulate tonic GluD1~R~-channel current {#s2-3}
---------------------------------------------------------------

To assess involvement of GluD1~R~-channels in carrying the α1-A~R~-EPSC, we applied 1-Naphthyl acetyl spermine (NASPM), a synthetic analogue of Joro spider toxin that is an open-channel blocker of some other Ca^2+^-permeable ionotropic glutamate receptors ([@bib9]; [@bib24]; [@bib40]) and of GluD~R~-channels ([@bib7]; [@bib39]). Application of NASPM (100 μM, 6 min) blocked the α1-A~R~-EPSC (96.0 ± 12.5% reduction), which recovered to baseline after a wash of \>30 mins ([Figures 3A, B, E and I](#fig3){ref-type="fig"}). NASPM also produced an apparent outward current (I~NSP~) of 20.5 ± 3.7 pA with an E~rev~ of −31.4 ± 4.8 mV ([Figures 3A, C, E and G](#fig3){ref-type="fig"}) and a reduction in membrane noise ([Figure 3A and D](#fig3){ref-type="fig"}). After washout, I~NSP~ reversed with a similar time course of recovery of the α1-A~R~-EPSC ([Figure 3E](#fig3){ref-type="fig"}). I~NSP~ was associated with an increase in R~m~ ([Figure 3F](#fig3){ref-type="fig"}) indicating a closure of channels. Replacing extracellular Na^+^ (126 mM) with NMDG eliminated I~NSP~ ([Figure 3G](#fig3){ref-type="fig"}). Thus, I~NSP~ was due to block of tonic Na^+^-dependent inward current. I~NSP~ was not dependent on prior electrical stimulation of the brain slice, as the magnitude of I~NSP~ was similar between stimulated and unstimulated brain slices ([Figure 3H](#fig3){ref-type="fig"}). Given that NASPM is an open-channel blocker ([@bib40]), we tested whether electrically evoking an α1-A~R~-EPSC during the application of NASPM was required for block. After obtaining a steady α1-A~R~-EPSC baseline, NASPM was applied for 6 min without stimulating the brain slice. The α1-A~R~-EPSC was blocked when stimulation was reapplied ([Figure 3I](#fig3){ref-type="fig"}), indicating that the channels underlying the α1-A~R~-EPSC were already blocked. Thus, the α1-A~R~-EPSC is mediated by channels that are at least transiently open at rest and may be the same channels underlie the apparent outward current induced by NASPM.

![NASPM blocks the α1-A~R~-EPSC and a tonic sodium inward current.\
(**A**) Example whole-cell voltage-clamp recording of the basal whole-cell current and the α1-A~R~-EPSC evoked every 90 s prior to, during, and after bath application of NASPM (NSP, 100 μM). Time of stimulations are marked by arrows and peak of the α1-A~R~-EPSC are marked by asterisks. (**B**) NASPM completely eliminated the α1-A~R~-EPSC shown in representative traces (left, baseline adjusted) and in grouped data (right, p=0.001, n = 8). (**C**) Bath application of NASPM produced an apparent outward current (p\<0.0001, n = 21). (**D**) Membrane noise (variance, σ^2^) decreased following NASPM (NSP, p\<0.0001, n = 19).(**E**) Time course of the inhibition of the α1-A~R~-EPSC amplitude (bottom) and apparent outward current (top) by application of NASPM. (**F**) Membrane resistance (R~m~, ΔV −65 to −75 mV) increased during bath application of NASPM, indicating the apparent outward current was due to ion channels closing (p=0.004, n = 10). (**G**) Current-voltage relationship of apparent outward current produced by NASPM (n = 8). Replacing 126 mM NaCl eliminated the apparent outward current (n = 11), suggesting a block of a tonic inward Na^+^ current. Shaded area represents mean ± SEM. (**H**) Plot of amplitude of NASPM-induced apparent outward current in stimulated and unstimulated brain slices demonstrating no effect of prior electrical stimulation (p=0.850, n = 21 and 5). (**I**) Time course of the inhibition of the α1-A~R~-EPSC amplitude by application of NASPM, demonstrating identical block of the α1-A~R~-EPSC whether or not α1-A~R~-EPSCs were evoked during NASPM application. Line and error bars represent mean ± SEM, ns indicates not significant, \* denotes statistical significance.\
Figure 3---source data 1.Numerical data that were used to generate graphs in [Figure 3](#fig3){ref-type="fig"}.](elife-56054-fig3){#fig3}

GluD~R~s bind the amino acids D-serine and glycine, both of which partially reduce constitutively open mutant and wild-type GluD~R~ channel current ([@bib1]; [@bib7]; [@bib48]; [@bib63]), likely by inducing a conformational change in the channel that resembles a desensitized state ([@bib27]). Application of D-serine (10 mM, 13.5 min) reduced the amplitude of the α1-A~R~-EPSC by 49.7 ± 9.6% ([Figure 4A and E](#fig4){ref-type="fig"}), without affecting unitary channel current ([Figure 4B](#fig4){ref-type="fig"}). Application of glycine (10 mM, 4.5 mins, in the presence of the glycine receptor antagonist, strychnine (10 μM), also reduced the amplitude of the α1-A~R~-EPSC by 70.9 ± 11.0% ([Figure 4C and E](#fig4){ref-type="fig"}), without affecting unitary channel current ([Figure 4D](#fig4){ref-type="fig"}). Lastly, we found that application of the glutamate receptor antagonist kynurenic acid (1 mM, 10.5 min) reduced the α1-A~R~-EPSC amplitude by 65.6 ± 8.3% ([Figure 4E](#fig4){ref-type="fig"}).

![D-serine and glycine reduce the α1-A~R~-EPSC.\
(**A**) Bath application of D-serine (10 mM) reversibly reduced the α1-A~R~-EPSC, shown in a representative trace (left) and in grouped data (right, p=0.001, n = 7). (**B**) Plot of α1-A~R~-EPSC variance versus mean amplitude prior to (ctrl) and after reduction by D-serine (D--S), linear fit represents mean unitary current (**i**), demonstrating no change in *i* with D-serine (p=0.165, n = 10 and 10). (**C**) Bath application of glycine (10 mM) reversibly reduced the α1-A~R~-EPSC, shown in representative traces (left, baseline adjusted) and in grouped data (right, p=0.015, n = 7). (**D**) Plot of α1-A~R~-EPSC variance versus mean amplitude prior to (ctrl) and after reduction by glycine (glyc), linear fit represents mean unitary current (**i**), demonstrating no change in *i* with glycine (p=0.895, n = 5 and 5). (**E**) Summarized data of percent remaining in α1-A~R~-EPSC after NASPM (NSP, 100 μM), D-serine (D-S, 10 mM), glycine (glyc, 10 mM), or kynurenic acid (KA, 1 mM). Line and error bars represent mean ± SEM, ns indicates not significant, \* denotes statistical significance.\
Figure 4---source data 1.Numerical data that were used to generate graphs in [Figure 4](#fig4){ref-type="fig"}.](elife-56054-fig4){#fig4}

Next, a viral genetic strategy was used to functionally delete GluD1~R-~channels by targeting the encoding gene, *Grid1*, via CRISPR/Cas9 ([Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). In brief, one of two cocktails of AAV1 viruses were microinjected into the dorsal raphe of wild-type mice. The *Grid1* cocktail that targeted GluD1~R~-channels included AAV1 viruses encoding Cas9, and mouse *Grid1* guide RNA with a nuclear envelope-embedded enhanced green fluorescent protein (eGFP) reporter. A separate cohort received a control cocktail of AAV1 viruses encoding Cas9 and eGFP reporter (control). Brain slices were prepared after \>4 weeks and the dorsal raphe was microdissected and frozen on dry ice to assess the mutation of *Grid1*. Restriction enzyme site-digested PCR confirmed in vivo mutation of *Grid1* at the expected site ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). In separate *Grid1* and control cohorts, brain slices were prepared and whole-cell voltage-clamp recordings were made from transduced and non-transduced neurons visualized in brain slices by expression of eGFP. In eGFP^+^ neurons from control mice, electrical stimulation produced a decrease in R~m~ and an α1-A~R~-EPSC, and bath application of noradrenaline caused inward I~NA~ ([Figure 5](#fig5){ref-type="fig"}). However, in eGFP^+^ neurons from *Grid1* mice, electrical stimulation did not change R~m~ ([Figure 5A](#fig5){ref-type="fig"}) and no α1-A~R~-EPSC was detected above baseline noise ([Figure 5B and C](#fig5){ref-type="fig"}). In addition, inward I~NA~ was substantially smaller in eGFP^+^ neurons from *Grid1* mice, as compared to eGFP^+^ neurons from control mice ([Figure 5D](#fig5){ref-type="fig"}). In the same slices from *Grid1* mice, eGFP^-^ neurons still had an α1-A~R~-EPSC and inward I~NA~ ([Figure 5B and D](#fig5){ref-type="fig"}). Lastly, bath application of NASPM produced an apparent outward current in eGFP^+^ neurons from control mice, but not from *Grid1* mice ([Figure 5E](#fig5){ref-type="fig"}). Taken together, these results demonstrate that conduction through GluD1~R~-channels is necessary for the α1-A~R~-EPSC and the NASPM-sensitive tonic inward current.

![The α1-A~R~-EPSC is eliminated by targeting of GluD1~R~-channels via CRISPR/Cas9.\
(**A**) Membrane resistance (R~m~, ΔV −65 to −120 mV) decreased after stimulation in transduced neurons from mice injected with AAV-Cas9 and AAV-empty (ctrl, p=0.0002, n = 13), but not in transduced neurons from mice injected with AAV-Cas9 and AAV-*Grid1* (*Grid1*, p=0.562, n = 16). (**B**) Representative traces (left) and grouped data (right, p\<0.0001, n = 15 and 16 and 7) demonstrating the presence of an α1-A~R~-EPSC in transduced neurons from control mice, but not from *Grid1* mice. Neighboring non-transduced neurons from mice injected with AAV-Cas9 and AAV-*Grid1* (non) had an α1-A~R~-EPSC that was indistinguishable from transduced neurons from control mice (p\>0.999). (**C**) Current-voltage relationship of the α1-A~R~-EPSC from control (n = 13) and *Grid1* (n = 16) grouped data. Shaded area represents mean ± SEM. (**D**) Targeting GluD1~R~ reduced the inward current to noradrenaline (NA, I~NA,~30 μM) as compared to transduced neurons from control mice and neighboring non-transduced neurons (p=0.004, n = 16 and 16 and 4). Inward I~NA~ in non-transduced neurons from mice injected with AAV-Cas9 and AAV-*Grid1* was similar to transduced neurons from control mice (p=0.631). (**E**) Targeting GluD1~R~ reduced the tonic inward current revealed by bath application of NASPM (100 μM, I~NSP~) as compared to transduced neurons from control mice (p=0.009, n = 5 and 11). Line and error bars represent mean ± SEM, \* denotes statistical significance, ns denotes not significant.\
Figure 5---source data 1.Numerical data that were used to generate graphs in [Figure 5](#fig5){ref-type="fig"}.](elife-56054-fig5){#fig5}

Functional deletion of GluD1~R~-channels in the dorsal raphe produces a behavioral phenotype {#s2-4}
--------------------------------------------------------------------------------------------

To assay a functional role of GluD1~R~-channels in dorsal raphe-related behavior, wild-type mice received a microinjection into the dorsal raphe of either *Grid1* or control virus cocktails. Behavioral assays were conducted \>4 weeks post-injection, then the accuracy of the dorsal raphe injection and limited-spread of transduction was verified post-hoc by immunohistochemistry ([Figure 6A](#fig6){ref-type="fig"}). Basal locomotion was assayed in a dark arena. There was no difference between the two groups in the total distance traveled ([Figure 6B](#fig6){ref-type="fig"}) nor in the velocity of movements between control and *Grid1* mice (p=0.772, n = 18 and 16, data not shown). Next, mice were tested on an elevated plus maze in a well-lit room, an experimental assay of rodent anxiety behavior ([@bib62]) known to involve both serotonergic and non-serotonergic neurons in the dorsal raphe ([@bib42]). *Grid1* mice spent less time in the open arms when compared to control mice ([Figure 6C--E](#fig6){ref-type="fig"}). Control and *Grid1* mice made a similar total number of entries to either open or enclosed arms (control: 39.4 ± 2.0; *Grid1*: 36.0 ± 2.3, p=0.697), but *Grid1* mice made proportionally fewer entries to the open arms ([Figure 6D](#fig6){ref-type="fig"}). Time spent grooming or in stretched-attend postures were similar between control and *Grid1* mice ([Figure 6F and G](#fig6){ref-type="fig"}). Since movement in the elevated plus maze reflects conflict between innate drive to explore of a novel environment and natural avoidance of open spaces ([@bib62]), we also examined exploratory behaviors. *Grid1* mice spent less time lowering their head over the edge of the open arms than control mice (head-dipping, [Figure 6H](#fig6){ref-type="fig"}), suggestive of decreased exploratory behavior. However, *Grid1* mice spent a similar amount of time rearing in the enclosed arms compared to control mice ([Figure 6I](#fig6){ref-type="fig"}) suggesting innate exploratory drive in the enclosed arms was intact. Taken together, these results are indicative of heightened anxiety after functional deletion of GluD1~R~-channels in the dorsal raphe.

![Loss of functional GluD1 receptors in the dorsal raphe produces an anxiogenic behavioral phenotype in mice.\
(**A**) Example maximum intensity projection confocal image of spread of viral transduction following dorsal raphe microinjection of AAV-Cas9 and AAV-*Grid1* using an eGFP reporter; scale bars, 0.5 mm. Image was registered and aligned with plate 69 (Franklin and Paxinos mouse brain atlas) with dorsal raphe outlined in solid white. (**B**) Plot of distance traveled in 30 mins in a dark arena, demonstrating no difference in horizontal locomotion between mice with dorsal raphe microinjections with AAV-Cas9 and AAV-empty (ctrl) versus with AAV-Cas9 and AAV-*Grid1* (p=0.762, n = 18 and 15). (**C**) In an elevated plus maze, *Grid1* mice spent less time in the open arms as compared with control-transduced mice (p=0.007, n = 10 and 10). (**D**) *Grid1* mice made proportionally fewer entries to the open arms compared to control-transduced mice (p=0.033, n = 10 and 10). (**E**) Plot of cumulative time spent in the open arms of an elevated plus maze (EPM). (**F**) Plot of time spent grooming, demonstrating no different between control-transduced and *Grid1* mice (p=0.481, n = 10 and 10). (**G**) Plot of time spent in stretched-attend posture, demonstrating no difference between control-transduced and *Grid1* mice (p=0.968, n = 10 and 9). (**H**) *Grid1* mice spent less time looking over the edge of the open arms (head-dip) than control-transduced mice (p=0.018, n = 10 and 10). (**I**) Plot of time spent rearing in the enclosed arms, demonstrating no difference between control-transduced and *Grid1* mice (p=0.143, n = 10 and 10). Line and error bars represent mean ± SEM, n = number of mice, \* denotes statistical significance, ns denotes not significant.\
Figure 6---source data 1.Numerical data that were used to generate graphs in [Figure 6](#fig6){ref-type="fig"}.](elife-56054-fig6){#fig6}

Discussion {#s3}
==========

Physiological relevance of GluD1~R~-channels to dorsal raphe function {#s3-1}
---------------------------------------------------------------------

In vivo, 5-HT neurons in the dorsal raphe require noradrenaline release and subsequent activation of α1-A~R~s to maintain persistent action potential firing ([@bib5]). The activation of α1-A~R~s in the dorsal raphe by exogenous agonist was thought to depolarize neurons through net reduction of K^+^ conductance, transiently activating calcium-activated K^+^ current while persistently decreasing another K^+^ current, and by activation of an unidentified non-K^+^ conductance ([@bib50]). In a more recent study in the dorsal raphe, [@bib11] reported that activation of α1-A~R~s, induces Na^+^-dependent inward current with an E~rev~ of −23 mV, similar to our findings. Our study identifies GluD1 receptor-channels as the ion channel that carries this mixed cation current, indicating that modulation of GluD1~R~-channels is a key constituent in driving persistent action potential firing of the 5-HT neurons. In principle, inward GluD1~R~-channel current may bring the membrane potential to threshold, but recruitment of other voltage-gated ion channels is expected to underlie the persistent pacemaker-like activity. Intriguingly, [@bib11] demonstrated that activation of G~q~ protein-coupled histamine H~1~ and orexin OX~2~ receptors also produced an inward current that was occluded by the α1-A~R~-dependent current. Whether these receptors, and other G~q~PCRs, augment GluD1~R~-channel current remains to be determined.

Dysregulation of the 5-HT signaling neuropsychiatric disorders is well-established. Pharmacotherapies to boost serotonin signaling are common and often efficacious in some of these conditions. Genetic association studies have identified *GRID1* as a susceptibility gene for psychiatric conditions, including schizophrenia, major depressive disorder, bipolar disorder, autism spectrum disorder, and alcohol dependence ([@bib14]; [@bib15]; [@bib23]). Global *Grid1* knock-out mice display abnormal social behaviors, including heightened aggression and decreased social interaction, as well as altered emotional behaviors ([@bib64]) that are analogous to features of neuropsychiatric conditions in humans. Our study found that functional deletion of GluD1~R~-channels, specifically in the dorsal raphe, produces a heightened anxiety-like response in the elevated plus maze without changing basal locomotion and exploratory behaviors in non-threatening environments. Previous studies have demonstrated that both 5-HT and non-5-HT/GABAergic dorsal raphe neurons are activated by aversive, anxiety or fear-producing stimuli ([@bib55]; [@bib57]), with regional subpopulation specificity ([@bib21]; [@bib22]; [@bib42]). Our viral strategy functionally deleted GluD1~R~-channels in a non-specific manner, targeting all dorsal raphe neurons, including 5-HT and GABAergic neurons. Given the rich diversity of dorsal raphe neuron subtypes and subdivisions within the 5-HT neurons ([@bib34]; [@bib46]; [@bib51]), future work will be needed to parse the behavioral role of GluD1~R~-channels with subnuclei/subpopulation specificity.

Metabotropic-ionotropic receptor crosstalk modulates ion channel function of GluD1~R~ {#s3-2}
-------------------------------------------------------------------------------------

GluD~R~ have been characterized as scaffold proteins or synaptic organizers, regulating LTD, endocytosis and trafficking of AMPA~R~, formation of excitatory and inhibitory synapses, and spine density, independent of ion conduction through the pore ([@bib16]; [@bib31]; [@bib54]; [@bib60]). Similarly, NMDA~R~ are known to signal through non-ionotropic or 'metabotropic' mechanisms where ion conduction is not required, to regulate LTD, AMPA~R~ endocytosis, and spine morphology ([@bib13]). The ability of GluD~R~-channels to carry ionic current does not conflict with its known role as a synaptic organizer, but rather expands the similarities between NMDA~R~ and GluD~R~.

The largest obstacle in advancing the understanding of the ionotropic nature of GluD~R~ is the lack of known agonist and inability to gate the intact channel. The majority of studies have been performed on constitutively open mutant or chimeric channels. In domain-swapped chimeric channels, agonist binding to the ligand-binding domain (LBD) of AMPA~R~ or Kainate~R~ opens the GluD~R~-channel pore and generates a substantial current, but the LBD of GluD~R~ on the pore region of AMPA~R~ or Kainate~R~-channels fails to generate current ([@bib49]; [@bib53]). Two prior studies have demonstrated that in heterologous systems and brain slices, activation of metabotropic glutamate receptors (mGlu~R~) produces an inward current carried by GluD1~R~- ([@bib7]) or GluD2~R~-channels ([@bib1]), concluding that mGlu~R~ activation triggers gating of GluD~R~ channels. The congruous explanation of our results is that, in dorsal raphe neurons, GluD1~R~-channels are functional and open under basal conditions, carrying subthreshold, tonic Na^+^ current. Activation of α1-A~R~s, by exogenous agonist or synaptic release of noradrenaline modulates gating of GluD1~R~-channels and excites dorsal raphe neurons by increasing tonic GluD1~R~-channel inward current.

In general, the kinetics of iGlu~R~ synaptic currents are controlled by the lifetime of the receptor-agonist complex and the rate of desensitization and deactivation. The presence of ambient levels of glutamate and glycine along with slow desensitization activate NMDA~R~ to produce a tonic inward current ([@bib52]). Our results demonstrate that GluD1~R~ are functional ion channels, but whether they function as ligand-gated receptor-channels that open in response to a chemical signal, is not yet determined. What remains to be understood are the conditions that permit GluD1~R~-channel opening and why their activation has been largely elusive in heterologous expression systems. Reminiscent of times before the discovery of glycine as a necessary co-agonist at NMDA~R~ ([@bib36]; [@bib38]), it may be that an endogenous agonist needed for gating is present in brain slices. Alternatively, it is possible GluD1~R~-channels are gated by an intracellular factor or require expression of accessory or interacting protein ([@bib61]). Tonic activation of α1-A~R~s cannot explain the tonic inward current as α1-A~R~ antagonism did not change basal whole-cell current.

The mechanism by which α1-A~R~s increase GluD1~R~-channel current also remains to be described and may be distinct from the tonic activation. It is well-established that G~q~PCRs, especially mGlu~R~ and mACh~R,~ bidirectionally change NMDA~R~ and AMPA~R~ ionic currents, producing the two major forms of synaptic plasticity, long-term potentiation (LTP) and long-term depression (LTD), in part through a variety of distinct postsynaptic mechanisms ([@bib35]). To our knowledge, the duration of the α1-A~R~-EPSC (\~27 s) is exceptional for any known synaptic current and more closely resembles the duration of short-term synaptic plasticity; for instance, endocannabinoid-mediated short-term depression ([@bib45]). Canonically, G~q~PCRs activate phospholipase C which hydrolyzes the integral membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP~3~) and diacylglycerol. PIP2 stabilizes Kv7 channels such that PIP2 hydrolysis following mACh~R~ activation accounts for inhibition of M-current ([@bib58]). In contrast, PIP2 inhibits TRPV4 channels, such that G~q~PCR-dependent PIP2 depletion allows for TRPV4 channels to open ([@bib28]). By the same signaling cascade, G~q~PCRs stimulate the production of the endocannabinoid, 2-AG, that can act directly on ion channels in the membrane ([@bib19]). Thus, one possibility is that α1-A~R~s modulate GluD1~R~-channels through membrane lipid signaling, involving PIP2, diacylglycerol, or 2-AG, as it can take tens-of-seconds to minutes for ion channels to recover from modulation by membrane lipids ([@bib19]; [@bib58]). Alternatively, there may be direct modulation of GluD1~R~-channels by G protein subunits or activation of protein kinase signaling cascades. The inclusion of the calcium-chelator BAPTA in the internal recording solution makes it unlikely that α1-A~R~s modulate GluD1~R~-channels via IP~3~ and calcium release from intracellular stores ([@bib32]). Largely, it remains to be seen whether these intracellular signaling cascades, many of which are known to affect NMDA~R~- and AMPA~R~-channels, modify GluD~R~-channels.

In heterologous systems and constitutively open mutant GluD~R~-channels, the current reverses polarity around 0 mV ([@bib67]), akin to AMPA~R~- and NMDAR-channels, while our results show E~rev~ of \~ −30 mV. While slow voltage-ramps were employed to minimize space-clamp error, we cannot rule out that some of the difference may be attributed to space-clamp error in brain slices, especially since the magnitude of subtracted current is small relative to total membrane current at depolarized potentials. However, there are many reports of inward currents produced by activation of many different G~q~PCRs with reversal potentials between −40 and −23 mV ([@bib3]; [@bib11]; [@bib65]) under different recording conditions; a commonality that is unlikely to be accounted for by space-clamp error alone. Tail current analysis revealed voltage-dependence of I~NA~, such that depolarization reduced conductance. These data may reflect block of GluD1~R~-channels by endogenous intracellular polyamines, as established for calcium-permeable AMPA~R~- and Kainate~R~-channels ([@bib10]). Another important consideration is that our measurements may be subject to voltage-dependence of the signaling pathway between α1-A~R~s and GluD1~R~-channels. Taken together, measurements here should be considered an estimate of GluD1~R~-channels, and more precisely as the current-voltage relationship of the α1-A~R~s-GluD1~R~-channel signaling complex.

Summary {#s3-3}
-------

In summary, the α1-A~R~-mediated depolarization of dorsal raphe neurons that drives action potential firing in vivo is carried by the mixed cation channel, GluD1~R~. Thus in addition to their role as a scaffold protein, GluD1~R~ are functional ion channels that critically regulate neuronal excitability. Many of the biophysical properties of the GluD1~R~-channel are like other members of the ionotropic glutamate receptor family. Given the widespread distribution of these receptors throughout the brain ([@bib30]), ion channel function of GluD1~R~ may be prevalent and relevant to neuronal excitability and circuit function in different parts of the throughout the nervous system. This study lays the foundation to investigate the ion channel function of GluD1~R~ in excitatory G~q~PCR-dependent synaptic transmission and regulation of neuronal excitability, expanding upon the wealth of knowledge of pharmacology and regulatory elements established for NMDA~R~ and AMPA~R~ signaling.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                    Source or\                                                        Identifiers                                                                                                                                 Additional\
  (species) or\                                                               reference                                                                                                                                                                                                     information
  resource                                                                                                                                                                                                                                                                                  
  -------------------------------------------- ------------------------------ ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Strain, strain background (*Mus musculus*)   C57BL/6J                       The Jackson Laboratory                                            Stock\# 000664\                                                                                                                             males and females
                                                                                                                                                RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)                                                                      

  Strain, strain\                              NEB Stable                     New England Biolabs                                               Cat\# C3040H                                                                                                                                \-
  background\                                                                                                                                                                                                                                                                               
  (*E. coli*)                                                                                                                                                                                                                                                                               

  Genetic reagent (adeno-associated virus)     AAV-Cas9                       PMIDs:[25326897](https://www.ncbi.nlm.nih.gov/pubmed/25326897)\   NIDA IRP Core Facility, AAV1, [pX551](https://www.addgene.org/60957/), RRID:[Addgene_60957](https://scicrunch.org/resolver/Addgene_60957)   Lot\# AAV692
                                                                              [30792150](https://www.ncbi.nlm.nih.gov/pubmed/30792150)                                                                                                                                                      

  Genetic reagent (adeno-associated virus)     AAV-*Grid1*                    This paper                                                        NIDA IRP Core Facility, AAV1, pOTTC1706,\                                                                                                   Lot\# AAV732
                                                                                                                                                Addgene 131683                                                                                                                              

  Genetic reagent (adeno-associated virus)     AAV-empty                      This paper                                                        NIDA IRP Core\                                                                                                                              Lot\# AAV746
                                                                                                                                                Facility, AAV1, pOTTC1553,\                                                                                                                 
                                                                                                                                                Addgene 131682                                                                                                                              

  Chemical compound, drug                      Bgl I restriction enzyme       New England\                                                      Cat\# R0143S                                                                                                                                \-
                                                                              Biolabs                                                                                                                                                                                                       

  Chemical compound, drug                      D-serine                       Millipore Sigma                                                   Cat\# S4250                                                                                                                                 10 mM

  Chemical compound, drug                      GDPβS-Li~3~                    Millipore Sigma                                                   Cat\# G7637                                                                                                                                 1.8 mM

  Chemical compound, drug                      Glycine                        Millipore Sigma                                                   Cat\# G7126                                                                                                                                 10 mM

  Chemical compound, drug                      Idazoxan                       Millipore Sigma                                                   Cat\# I6138                                                                                                                                 1 μM

  Chemical compound, drug                      Kynurenic acid                 Millipore Sigma                                                   Cat\# K3375                                                                                                                                 1 mM

  Chemical\                                    MK-801                         Tocris Bioscience                                                 Cat \#0924                                                                                                                                  5 μM
  compound,\                                                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                                                      

  Chemical compound, drug                      NASPM                          Tocris Bioscience                                                 Cat \#2766                                                                                                                                  100 μM

  Chemical compound, drug                      NBQX                           Tocris Bioscience                                                 Cat \#1044                                                                                                                                  3 μM

  Chemical compound, drug                      NMDG                           Millipore Sigma                                                   Cat\# 66930                                                                                                                                 126 mM

  Chemical compound, drug                      Noradrenaline                  Tocris Bioscience                                                 Cat \#5169                                                                                                                                  30 μM

  Chemical compound, drug                      Picrotoxin                     Tocris Bioscience                                                 Cat \#1128                                                                                                                                  100 μM

  Chemical compound,\                          Prazosin                       Millipore Sigma                                                   Cat\# P7791                                                                                                                                 100 nM
  drug                                                                                                                                                                                                                                                                                      

  Chemical compound, drug                      Reserpine                      Millipore Sigma                                                   Cat\# R0875                                                                                                                                 1 μM

  Chemical compound, drug                      Strychnine                     Millipore Sigma                                                   Cat\# S8753                                                                                                                                 10 μM

  Chemical compound, drug                      Tetrodotoxin                   Tocris Bioscience                                                 Cat\# 1069                                                                                                                                  1 μM

  Chemical compound, drug                      WAY-100635                     Tocris Bioscience                                                 Cat\# 4380                                                                                                                                  300 nM

  Sequence-based reagent                       Forward amplification primer   IDTDNA                                                            tgattacgccaagctt\                                                                                                                           \-
                                                                                                                                                GGTGGAGCTGTGTGGATGAAGC                                                                                                                      

  Sequence-based\                              Forward\                       IDTDNA                                                            CCAGCCTGTGACCTCATGACC                                                                                                                       \-
  reagent                                      sequence primer                                                                                                                                                                                                                              

  Sequence-based reagent                       Reverse amplification primer   IDTDNA                                                            gacggccagtgaattc CTTCAGCTGTCATGATAAGGTGATGTTG                                                                                               \-

  Commercial assay, kit                        In-Fusion HD Cloning           Takara Bio Clontech                                               Cat\# 639647                                                                                                                                \-

  Software,\                                   Clampfit 10.7                  Axon Instruments                                                  RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)                                                                                <https://www.moleculardevices.com/products/axon-patch-clamp-system>
  algorithm                                                                                                                                                                                                                                                                                 

  Software, algorithm                          EthoVision XT                  Noldus Information Technology                                     RRID:[SCR_000441](https://scicrunch.org/resolver/SCR_000441)                                                                                <https://www.noldus.com/ethovision-xt>

  Software, algorithm                          Fiji                           PMID:[22743772](https://www.ncbi.nlm.nih.gov/pubmed/22743772)     RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                                                                                <http://fiji.sc>

  Software, algorithm                          Prism 8                        GraphPad                                                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                                                                <http://www.graphpad.com>

  Software,\                                   VersaMax Analyzer              Omnitech-electronics, Inc                                         <http://www.omnitech-electronics.com/product/VersaMax-Legacy-Open-Field---Locomotor-Activity/1930>                                          \-
  algorithm                                                                                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

All studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory animals with the approval of the National Institute on Drug Abuse Animal Care and Use Committee. Wild-type C57BL/6J (\>3 months old) mice of either sex were used. Mice were group-housed on a 12:12 hr reverse light cycle.

Brain slice preparation and electrophysiological recordings {#s4-2}
-----------------------------------------------------------

The methods for brain slice preparation and electrophysiological recordings were almost identical to previous reports in the dorsal raphe ([@bib17]) and ventral midbrain ([@bib18]). In brief, mice were deeply anesthetized with isoflurane and killed by decapitation. Brains were removed quickly and placed in warmed artificial cerebral spinal fluid (modified Krebs' buffer) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl~2~, 1.2 CaCl~2~, 1.2 NaH~2~PO~4~, 21.5 NaHCO~3~, and 11 D-glucose with 5 μM MK-801 to reduce excitotoxicity and increase viability, bubbled with 95/5% O~2~/CO~2~. In the same solution, coronal dorsal raphe slices (220 μm) were obtained using a vibrating microtome (Leica 1220S) and incubated at 32°C \> 30 min prior to recording.

Slices were then mounted in a recording chamber and perfused \~3 mL/min with \~35°C modified Krebs' buffer. Electrophysiological recordings were made with a Multiclamp 700B amplifier (Molecular Devices), Digidata 1440A A/D converter (Molecular Devices), and Clampex 10.4 software (Molecular Devices) with borosilicate glass electrodes (King Precision Glass) wrapped with Parafilm to reduce pipette capacitance ([@bib19]). Pipette resistances were 1.8--2.8 MΩ when filled with an internal solution containing, (in mM) 104.56 K-methylsulfate, 5.30 NaCl, 4.06 MgCl~2~, 4.06 CaCl~2~, 7.07 HEPES (K), 3.25 BAPTA(K4), 0.26 GTP (sodium salt), 4.87 ATP (sodium salt), 4.59 creatine phosphate (sodium salt), pH 7.32 with KOH, mOsm \~285, for whole-cell patch-clamp recordings. Series resistance was monitored throughout the experiment. Transmitter release was evoked by trains of electrical stimuli delivered via a Krebs' buffer-filled monopolar stimulating electrode positioned in the dorsal raphe, within 200 μm of the recorded neuron ([@bib17]). Cell-attached recordings were made from quiescent neurons in slice, using pipettes filled with modified Krebs' buffer. For experiments involving viral microinjections, transduced neurons were identified in the slice by visualization of eGFP. Reported voltages are corrected for a liquid junction potential of −8 mV between the internal solution and external solution. All drugs were applied by bath application. All experiments were conducted following incubation in an NMDA~R~ channel blocker (MK-801, 5 μM,\>1 hr), and then with AMPA~R~ and Kainate~R~ (NBQX, 3 μM), GABA-A~R~ (picrotoxin, 100 μM), and 5-HT1A~R~ (WAY-100635, 300 nM) antagonists in the external solution. In addition, a α2-adrenergic receptor antagonist (idazoxan, 1 μM) was added for experiments where noradrenaline was applied and a glycine receptor antagonist (strychnine, 10 μM) was added when glycine was applied. Unitary current was calculated from fluctuation analysis, as previously described ([@bib6]), assuming the macroscopic current arises from independent, identical channels with a low probability of opening, according probability theory; *i* = σ^2^/\[*I*(1 p)\] where *i* is unitary current, σ^2^ is the variance, *I* is mean current amplitude, and *p* is probability of opening.

Vector construction gRNA identification {#s4-3}
---------------------------------------

CRISPR SpCas9 gRNA target sites were identified in the mouse *Grid1* gene (NC_000080.6) using CRISPOR ([@bib25]). The seed sequence (GAACCCTAGCCCTGACGGCG) was chosen based on its relatively high specificity scores and the observation that it contains a Bgl I restriction enzyme site (GCCNNNN\^NGGC) that overlaps with the Cas9 cleavage site.

Mouse *Grid1* genotyping {#s4-4}
------------------------

C57BL/6J mouse genomic DNA was isolated from tail biopsies or brain pieces containing microdissected dorsal raphe by digestion in DNA lysis buffer (50 mM KCl, 50 mM Tris-HCl (pH 8.0), 2.5 mM EDTA, 0.45% NP-40, 0.45% Tween-20, 0.5 ug/mL proteinase K) for 3 hr at 55°C, and 1 hr at 65°C. Lysates were then used as templates to amplify a 654 basepair fragment including the 390F gRNA target site using Q5 HotStart Master mix (New England Biolabs). A portion of the finished PCR reaction was treated with Bgl I restriction enzyme (New England Biolabs) for 60 min and processed on an AATI fragment analyzer.

Construction and packaging of AAV vectors {#s4-5}
-----------------------------------------

The AAV vector plasmid encoding SpCas9 ([@bib59]) (pX551) expressed from the *Mecp2* promoter was a gift from Feng Zhang (Addgene plasmid \# 60957, AAV-Cas9). The AAV packaging plasmid encoding a nuclear envelope-embedded eGFP reporter (Addgene 131682) was constructed by amplifying the KASH domain from (Addgene 60231, a gift of Feng Zhang) and fusing it (in-frame) to the end of coding region for eGFP in (Addgene 60058, pOTTC407) using ligation-independent cloning (AAV-empty, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). gRNA was cloned into a mU6 expression cassette and then moved into an AAV backbone expressing a nuclear envelope-embedded (KASH-tagged) eGFP reporter (Addgene 131683) by PCR amplification and ligation-independent cloning (AAV-*Grid1*). Insert-containing clones were verified by sequencing and restriction fragment analysis prior to virus production. All AAV vectors were produced using triple transfection method as previously described ([@bib33]). All vectors were produced using serotype 1 capsid proteins and titered by droplet digital PCR.

Stereotaxic intracranial microinjections {#s4-6}
----------------------------------------

Mice were anesthetized with a cocktail of ketamine/xylazine, immobilized in a stereotaxic frame (David Kopf Instruments), and received one midline injection of a 1:1 (v/v) cocktail of viruses AAV-Cas9 and AAV-empty or AAV-*Grid1* for total volume 400 nL delivered over 4 min. The coordinates for injection were AP −4.4; ML 1.19, 20° angle; DV −3.62 mm, with respect to bregma. Prior to surgery, mice were injected subcutaneously with warm saline (0.5 mL) to replace fluid lost during surgery and given carprofen (5 mg/kg) post-surgery for pain relief. Mice recovered for \>4 weeks to allow expression.

Behavioral assays {#s4-7}
-----------------

Behavioral assays were conducted during the dark cycle, using 3 separate cohorts of AAV-Cas9 and AAV-empty or AAV-*Grid1*-injected mice as biological replicates, 30--55 d post-injection. To measure basal locomotion, mice were placed in locomotor boxes (VersaMax System, Omnitech Electronics, Inc) in a dark room for 1 hr, following prior habituation to the locomotor boxes for \>2 d (1 hr/d). VersaMax Analyzer software was used to determine the total distance traveled, time spent moving, and velocity of movement in the last 30 min of the session. The boxes were cleaned with 70% ethanol and allowed to dry between trials. The elevated-plus maze was used to assay anxiety-related behaviors ([@bib62]). The apparatus (Med associates, Inc) was placed 30 cm above the floor and consisted of two plastic light gray open arms (30 × 5 cm) and two black enclosed arms (30 × 5 cm) extending from a central platform (5 × 5 × 5 cm) at 90 degrees. Following habituation to the brightly lit room, mice were placed individually in the center of the maze, facing an open arm. Video tracking EthoVision XT software (Noldus Information Technology) was used to track mouse location, total distance traveled, velocity of movement, body elongation, and entries and time spent into the open and enclosed arms for each 5 min trial. Duration of head-dips, grooming, and enclosed-arm rearing were scored manually from videos played a 0.5x speed. Rearing in the enclosed arm was often associated with pressing one or both forepaws to the wall. Stretched-attend postures was defined by body elongation (70% threshold) and movement velocity \<1 cm/s. No mice fell or jumped from the maze and open-arm rearing was not observed. The maze was cleaned with 70% ethanol after every trial and allowed to dry before the next trial. Mice were excluded from analysis if there was limited or no expression in the dorsal raphe, or if expression spread rostrally to the ventral tegmental area or caudally to locus coeruleus.

Immunohistochemistry and confocal microscopy {#s4-8}
--------------------------------------------

Following behavioral assays, mice were euthanized with Euthasol and transcardially perfused with PBS followed by ice-cold 4% paraformaldehyde in PBS (pH 7.4). Brains were fixed overnight at 4 C and then sliced coronally in 50 μm sections. Alternatively, mice were anesthetized with isoflurane and euthanized by decapitation. Brains were removed and slices were prepared as for brain slice electrophysiology (220 μm), then fixed in room temperature 4% paraformaldehyde in PBS for 1 hr. Slices were mounted with Fluoromount-G with DAPI (Invitrogen) aqueous mounting medium. Confocal images were collected on an Olympus microscope (4x, 0.16 NA) and processed using Fiji.

Data analysis and visualization {#s4-9}
-------------------------------

Data were analyzed using Clampfit 10.7. Data are presented as representative traces, or in scatter plots where each point is an individual cell, and bar graphs with means ± SEM. In traces with electrical stimulation, stimulation artifacts have been blanked for clarity. Unless otherwise noted, *n* = number of distinct cells or mice as biological replicates. No sample was tested in the same experiment more than once (technical replication). E~rev~s were determined by linear regression for each cell. Recordings in which current did not cross 0 pA were omitted from analysis. To minimize space-clamp errors, analysis of current during voltage ramps was limited to −10 mV where the currents were typically less than 500 pA. Ramp currents were averaged in 2 mV bins (20 ms). Data sets with n \> 30 were tested for normality with a Shapiro-Wilk test. When possible (within-group comparisons), significant differences were determined for two group comparisons by paired t-tests, Wilcoxon matched-pairs signed rank test, and in more than two group comparisons by nonparametric repeated-measures ANOVA (Friedman test). Significant mean differences in between-group comparisons were determined for two group comparisons by Mann Whitney tests, and in more than two group comparisons by Kruskal-Wallis tests. ANOVAs were followed, when p\<0.05 by Dunn's multiple comparisons post hoc test. Linear trends were analyzed using a mixed model ANOVA. A difference of p\<0.05 was considered significant. For behavioral assays, Grubbs test was used to identify outliers. Basal locomotion and time spent in stretched-attend posture from one *Grid1* mouse each were found to be outliers and were excluded from group comparisons. Exact values are reported unless p\<0.0001 or\>0.999. Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, Inc).
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**Acceptance summary:**

This study provides an elegant and convincing pharmacological and biophysical demonstration that the orphan δ glutamate receptor is responsible for α-Adrenergic receptor-mediated depolarization of dorsal raphe neurons. Genetic tools reveal how a nanoscale alteration (cell type specific deletion of GluD in in the dorsal raphe) leads to macroscale behavioral disturbances.
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This study provides an elegant and convincing pharmacological and biophysical demonstration that the orphan δ glutamate receptor is responsible for α-Adrenergic receptor-mediated depolarization of dorsal raphe neurons. Astute genetic tools are used to show how a nanoscale alteration (cell type specific deletion of GluD in in the dorsal raphe) leads to macroscale disturbances (anxiogenic behaviors).

Essential revisions:

1\) Improve the form of the manuscript (no experiments required; analysis and rewriting required):

1A) Abstract

The Abstract summarizes the principal point of the paper with \"We show that a1-AR-mediated excitatory synaptic transmission is mediated by δ glutamate receptors (GluD1~R~).\" To paraphrase, this sounds like \"The response mediated by receptor X is mediated by receptor Y,\" This sentence and possibly others like it do not do justice to the paper and should be improved. Clarify that the main and important discovery is that the a1-AR-mediated postsynaptic depolarization of raphe neurons results from the G-protein coupled modulation of a non-selective cation channel. This channel happens to be named δ glutamate receptor (GluD1~R~), but that may be a distracting misnomer. It may not be glutamate responsive, and is, so far, an orphan ionotropic receptor homolog that may not act as a receptor at all. It is an ion channel at least.

1B) Materials and methods:

-- You say, \"With cell-attached recordings, a train of 5 electrical stimuli (60 Hz) produced firing in previously quiescent neurons.\"

Because this stimulation was key in demonstrating physiological effects it is important to clearly explain where or how the cell is stimulated (was a stimulus applied extracellularly to some other part of the slice?).

-- The part about the preparation is written without references or detail as if everyone would know what was done already. Indeed, the whole Materials and methods section makes little reference to the literature except for a reference to noise analysis and one to how to generate AAV virus tools.

-- Concentrations for the antagonists should be mentioned.

1C) Figures:

-- Adding color in the figures would help readers.

-- Some of the supplementary figures could easily be incorporated into the main figures, as they are important controls. For example, why not include Figure 1---figure supplement 1 in the main figure? The same stands for Figure 2---figure supplements 1 and 2. Figure 6---figure supplements 1 and 2 could be combined to 1 package (remaining as a supplement).

1D) Results:

-- You write \"We applied the channel selective Joro spider toxin, 1-Naphthyl acetyl spermine (NASPM), which is an open-channel blocker GluD~R~, akin to other Ca^2+^-permeable ionotropic glutamate receptors (Benamer et al., 2018; Blaschke et al., 1993; Guzmán et al., 2017; Kohda et al., 2000)."

Please rephrase: We applied 1-Naphthyl acetyl spermine (NASPM), a synthetic analogue of Joro spider toxin that is an open-channel blocker of some other Ca^2+^-permeable ionotropic glutamate receptors and of GluD~R~ channels (Koike, Iino and Ozawa, 1997).

-- You write, \"GDP-bS-Li3.\"

GDPbS-Li3 would be a more familiar name for this compound.

-- The behavioral analysis is very limited, especially in comparison with the depth of the biophysical data. At the very least the authors should report rears, head dips, freezing and stretched-attend postures, from their EPM experiments (i.e. already been performed).

1E) Discussion:

-- The reversal potential of -20 mV suggests that the channel would be twice as permeable to K as to Na\--if it really is the response from one channel type in a space-clamped cell. In the Discussion however the authors draw back from being sure that it is one channel and that there is space clamp.

-- The signal from the adrenergic receptor to the depolarizing channel is not yet specified. The MS stimulates mechanistic questions on intracellular signaling that I hope will be addressed in future work, including: Would other Gq-coupled receptors activate this channel? Can the phenomena be reproduced in expression systems? Is GluD~R~ activated via any of the following traditional α-1 signaling pathways: IP3-Ca, DAG-PKC, PIP2 depletion, or arrestin-Mek-Erk? Could any of them explain why the epsc response has such a long latency and such long persistence? These points could be added to the Discussion.

-- What explains the incomplete blockade by glycine+strychnine, D-Serine and Kynurenate? Additional a1-AR mediated but not GluD~R~-mediated mechanisms (although the elimination of a1-AR-EPSC by targeting of GluD1 receptors via CRISPR/Cas9 argues against this idea)? Non saturating doses of antagonists?

2\) Clarify and expand the current data set (additional experiments may be required):

2A) Figure 1:

It would be great to see the contribution of GluD1~R~ compared to traditional ionotropic signaling in Figure 1A. In other words, an example of stimulation in the absence of the AMPA/NMDA/GABA-A/5-HT1A antagonist cocktail, chased with the cocktail to then show the remaining GluD1~R~ mediated synaptic event.

2B) Figure 7:

If animals are available, the authors may consider 1/ testing the (acute) effects of SSRIs on the reported anxiogenic phenotype and/or 2/ evaluating how the lack of functional GluD1 receptors in the dorsal raphe impact social interaction and social memory (both likely to reflect the elevated anxiety reported here). If time was not a concern, one may also evaluate how knocking out GluD-a1-AR impacts on the susceptibility to stress and stress-induced depressive behaviors.

10.7554/eLife.56054.sa2

Author response

> Essential revisions:
>
> 1\) Improve the form of the manuscript (no experiments required; analysis and rewriting required):
>
> 1A) Abstract
>
> The Abstract summarizes the principal point of the paper with \"We show that a1-AR-mediated excitatory synaptic transmission is mediated by δ glutamate receptors (GluD1~R~).\" To paraphrase, this sounds like \"The response mediated by receptor X is mediated by receptor Y,\" This sentence and possibly others like it do not do justice to the paper and should be improved. Clarify that the main and important discovery is that the a1-AR-mediated postsynaptic depolarization of raphe neurons results from the G-protein coupled modulation of a non-selective cation channel. This channel happens to be named δ glutamate receptor (GluD1~R~), but that may be a distracting misnomer. It may not be glutamate responsive, and is, so far, an orphan ionotropic receptor homolog that may not act as a receptor at all. It is an ion channel at least.

This is an excellent point. As suggested, we have changed the Abstract to emphasize modulation of a non-selective cation channel. Through-out the text, we now refer to the ion channel as the "δ glutamate receptor-channel" or "GluD1~R~ channel", and "ionotropic function" has been changed to "ion channel function". Lastly, we have stated in the Discussion that our study shows that GluD1~R~ acts as an ion channel, but not necessarily a ligand-gated ionotropic receptor, in so far as the identify of a chemical messenger or ligand responsible for activation, if it exists, remains unknown.

> 1B) Materials and methods:
>
> -- You say, \"With cell-attached recordings, a train of 5 electrical stimuli (60 Hz) produced firing in previously quiescent neurons.\"
>
> Because this stimulation was key in demonstrating physiological effects it is important to clearly explain where or how the cell is stimulated (was a stimulus applied extracellularly to some other part of the slice?).

Yes, all stimuli were applied via a monopolar electrode placed in the brain slice within 200 microns to the recorded neurons. We have now included more details on the methodology in the Results and Materials and methods sections, as well as reference prior studies with similar methodology.

> -- The part about the preparation is written without references or detail as if everyone would know what was done already. Indeed, the whole Materials and methods section make little reference to the literature except for a reference to noise analysis and one to how to generate AAV virus tools.

More details and references have now been added to the Materials and methods section. We thank the reviewers for bringing this to our attention.

> -- Concentrations for the antagonists should be mentioned.

These are now included in the new revised manuscript.

> 1C) Figures:
>
> -- Adding color in the figures would help readers.

We have added color to the new Figures 2, 5, and 6 to help readability.

> -- Some of the supplementary figures could easily be incorporated into the main figures, as they are important controls. For example, why not include Figure 1---figure supplement 1 in the main figure?

Figure 1---figure supplement 1 is now included in Figure 1.

> The same stands for Figure 2---figure supplements 1 and 2.

Figure 2---figure supplement 1, Figure 2---figure supplement 2, and Figure 3 are now included in Figure 2. Subsequent figures numbers have adjusted to reflect the combination of Figure 2 and Figure 3.

> Figure 6---figure supplements 1 and 2 could be combined to 1 package (remaining as a supplement).

Figure 6---figure supplements 1 and 2 are now combined into one supplementary figure (Figure 5---figure supplement 1).

> 1D) Results:
>
> -- You write \"We applied the channel selective Joro spider toxin, 1-Naphthyl acetyl spermine (NASPM), which is an open-channel blocker GluD~R~, akin to other Ca^2+^-permeable ionotropic glutamate receptors (Benamer et al., 2018; Blaschke et al., 1993; Guzmán et al., 2017; Kohda et al., 2000)."
>
> Please rephrase: We applied 1-Naphthyl acetyl spermine (NASPM), a synthetic analogue of Joro spider toxin that is an open-channel blocker of some other Ca^2+^-permeable ionotropic glutamate receptors and of GluD~R~ channels (Koike, Iino and Ozawa, 1997).

This has been rephrased with the suggested reference.

> -- You write, \"GDP-bS-Li3.\"
>
> GDPbS-Li3 would be a more familiar name for this compound.

This is corrected in the revised manuscript.

> -- The behavioral analysis is very limited, especially in comparison with the depth of the biophysical data. At the very least the authors should report rears, head dips, freezing and stretched-attend postures, from their EPM experiments (i.e. already been performed).

We have now included time spent grooming, head-dipping off the open arms, rearing in the enclosed arms, and stretched-attend postures. The data show a selective deficit in exploratory behavior in the open arms (head-dipping) following GRID1 deletion while rearing in the enclosed arms was similar to control mice. We thank the reviewers for this suggestion. The new data advances the understanding of the phenotype.

> 1E) Discussion:
>
> -- The reversal potential of -20 mV suggests that the channel would be twice as permeable to K as to Na\--if it really is the response from one channel type in a space-clamped cell. In the Discussion however the authors draw back from being sure that it is one channel and that there is space clamp.

We have extensively revised this Discussion paragraph. By our calculations using a reversal potential of -30 mV, and the shift in reversal potentials observed with changing extracellular potassium, we estimate the channel may be 2 to 3 times as permeable to potassium as sodium, now included in the Results.

Regarding the issue of space-clamp error, we feel it is important to acknowledge that recordings in brain slices can particularly susceptible to some space-clamp error, without careful consideration. In our study, all efforts were made to reduce space-clamp errors, including the use of slow voltage ramps (1 mV/10 mS) where data were binned every 20 ms. Voltage ramps were made from -120 to -10 mV where the size of the total membrane current was less than 500 pA. Further, we also used voltage steps (10 mV increments, 150 ms duration) to generate current-voltage plots of the current induced by exogenous noradrenaline, and obtained identical E~rev~s (data not shown in the manuscript). Thus, we do not believe that space-clamp error accounts for the difference in reports of reversal potential of constitutively open mutant GluD~R~ channels (0 mV) and our data (\~ -30 mV). These points are clarified in the revised text.

Regarding the issue of the one channel, the results following functional deletion of GluD1~R~ indicate that the α1-A~R~-dependent *inward* current is carried completely by GluD1~R~ channels. We have removed reference to inhibition of A-type potassium current by α1-A~R~ activation (Aghajanian, 1985). While an important finding, the data from our study do not support involvement of A-type channels in the α1-A~R~-EPSC.

> -- The signal from the adrenergic receptor to the depolarizing channel is not yet specified. The MS stimulates mechanistic questions on intracellular signaling that I hope will be addressed in future work, including: Would other Gq-coupled receptors activate this channel? Can the phenomena be reproduced in expression systems? Is GluD~R~ activated via any of the following traditional α-1 signaling pathways: IP3-Ca, DAG-PKC, PIP2 depletion, or arrestin-Mek-Erk? Could any of them explain why the epsc response has such a long latency and such long persistence?
>
> These points could be added to the Discussion.

We have revised this part of the Discussion to include these points. In brief, it remains to be determined whether other GqPCRs augment GluD1~R~ channel current. Brown et al., 2002 (cited in the manuscript) find that the α1-A~R~-dependent inward current occludes an inward current produced by activation of Gq-coupled histamine and orexin receptors. This suggests that these receptors may also be modulating GluD1~R~ channels, but it has not yet been tested.

In regard to expression systems, Benamer et al., 2018, were able to measure mGluR-GluD1~R~ current in HEK cells suggesting we may be able to reproduce our α1-A~R~ phenomena in expression systems. Instead of expression systems, we will be working towards recordings from acutely dissociated dorsal raphe neurons to see if the tonic current requires brain slice work. This model will allow for better voltage control and high-throughput screening of drugs and then extend our findings to expression systems.

In regard to the mechanism, the inclusion of intracellular BAPTA in the recording solution makes it unlikely that α1-A~R~s are modulating GluD1~R~ channels via IP~3~-Ca^2+^. Involvement of PIP2 hydrolysis to DAG, and the subsequent signaling cascade is a very viable possibility. The duration of the α1-A~R~s (on average 27s, but can persist up to 90s) is similar to time course of recovery (tens-of-seconds to minutes) of M-current inhibition following PIP2 hydrolysis and inhibition of A-type potassium current by 2-AG (citations in manuscript). Alternatively, there may be direct modulation by G protein subunits, activation of protein kinase signaling cascades (e.g. Arrestin-MEK-ERK, or PKC), or a combination of effectors, akin to GIRK channel gating by Gβγ subunits and PIP2. We feel to present the results comprehensively, they are best fleshed out in a full follow-up study. But these possibilities are now discussed in the revised manuscript.

> -- What explains the incomplete blockade by glycine+strychnine, D-Serine and Kynurenate? Additional a1-AR mediated but not GluD~R~-mediated mechanisms (although the elimination of a1-AR-EPSC by targeting of GluD1 receptors via CRISPR/Cas9 argues against this idea)? Non saturating doses of antagonists?

This is a great question. In other publications, there is never complete elimination of GluD~R~ channel current at concentrations up to 10 mM. D-serine or glycine reduce GluD~R~ channel current, with reports of near complete reduction of the *Lurcher* GluD2~R~ mutant (\~25% of the current remains, e.g. Naur et al., 2007) and wild type GluD2~R~ (\~35% of current remains, Ady et al., 2013) but partial reduction of mutant GluD1~R~ (\~50-60% of the current remains, Yadav et al., 2011) and wild type GluD1~R~ (60% of the current remains, Benamer et al., 2018). The reductions we observe are consistent with these GluD1~R~ reports.

What explains incomplete blockade at a structural level is not completely understood. Hansen et al., 2009 (now referenced in the revised manuscript) examined the structural basis for reduction of constitutively open *Lurcher* GluD2~R~ channel current. Their conclusion is that binding of D-serine puts Lurcher GluD2~R~ in a closed but desensitized state. No similar study has been performed yet for GluD1~R~. In the revised manuscript, we have added new data examining membrane noise during the EPSC in control conditions and after reduction by D-serine or glycine. We report that there was no change in unitary channel current (Figure 4B and D) with D-serine nor glycine. The simplest explanation is that there is a change in the number of open channels, but further work will be needed to determine the structural basis for reduction. To make this clearer, we have revised the manuscript. Instead of stating these amino acids "inhibit" GluD~R~ channel current, we write that they "partially reduce" GluD~R~ channel current and reference these studies.

Our manuscript is the first to report reductions in GluD1~R~ channel-current by kynurenic acid. We discovered this serendipitously after initially using kynurenic acid to inhibit NMDA~R~ channel synaptic currents. This may be unique to GluD1~R~ channel current over GluD2~R~, as Kristensen et al. (2016, Mol Pharm) reported that Lurcher GluD2~R~ channel current is not sensitive to kynurenic acid but is reduced by the kynurenic acid analog, 7-chlorokynurenic acid (7-CKA). We feel it is best for reproducibility to report the effect of kynurenic acid since it is used commonly to inhibit NMDA~R~ synaptic responses. Then as a follow-up study, we will screen other known compounds and generate concentration-response curves as in Kristensen et al., 2016.

> 2\) Clarify and expand the current data set (additional experiments may be required):
>
> 2A) Figure 1:
>
> It would be great to see the contribution of GluD1~R~ compared to traditional ionotropic signaling in Figure 1A. In other words, an example of stimulation in the absence of the AMPA/NMDA/GABA-A/5-HT1A antagonist cocktail, chased with the cocktail to then show the remaining GluD1~R~ mediated synaptic event.

The revised manuscript now includes contribution of GluD1~R~ channel synaptic current in comparison to fast synaptic transmission and slow 5-HT1A~R~ synaptic transmission (Figure 1H). In this experiment, NMDA~R~ channels were blocked by MK-801, but contribution from NMDA~R~ channels at holding potential of -65 mV is expected to be minimal due to magnesium block. Otherwise, the experimental design is as suggested by the reviewers. We stimulated in the absence of AMPA/GABA-A/5-HT1A antagonists, then chased with a cocktail of antagonists to reveal only the GluD1~R~ channel-mediated current. We hope the addition of this figure helps illustrate the duration of the GluD1~R~ channel-mediated synaptic current.

> 2B) Figure 7:
>
> If animals are available, the authors may consider 1/ testing the (acute) effects of SSRIs on the reported anxiogenic phenotype and/or 2/ evaluating how the lack of functional GluD1 receptors in the dorsal raphe impact social interaction and social memory (both likely to reflect the elevated anxiety reported here). If time was not a concern, one may also evaluate how knocking out GluD-a1-AR impacts on the susceptibility to stress and stress-induced depressive behaviors.

We are also very interested in extending the behavioral phenotype to examine other social and stress-induced behaviors. It is a great suggestion to test the effects of SSRIs. However, we feel it is beyond the scope of the present study. These questions will be addressed more completely in a study where we also evaluate the impact of the lack of functional GluD1~R~ in the dorsal raphe on serotonin release and serotonin receptor-dependent signaling.
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